No HIV-1 molecular evolution on long-term antiretroviral therapy initiated during primary HIV-1 infection
OBJECTIVE: Most studies about HIV-1 molecular evolution have shown the lack of viral evolution on effective antiretroviral therapy (ART), although controversial results have been documented. We therefore aimed to look for evidence of HIV-1 evolution in patients who initiated ART at the time of primary HIV-1 infection (PHI).
DESIGN: We included retrospectively 20 patients diagnosed at PHI, treated at the time of acute infection and with subsequent effective long-term suppressive ART (HIV viral load <20 copies/ml during at least 5 years without any blips).
METHODS: Longitudinal blood samples were deep sequenced using Illumina Miseq. Drug-resistance-associated mutations were retained at 2% cutoff and interpreted using the latest Agence Nationale de Recherches sur le Sida et les Hépatites Virales resistance algorithm. Viral evolution was established when temporal structure on maximum-likelihood phylogenetic tree and significant change over time of HIV-1 genetic diversity measured as the average pairwise distance was observed.
RESULTS: Emergences or disappearances of drug-resistance-associated mutations were detected in the blood cells during follow-up despite sustained virological control. In all patients, tree topologies showed an absence of segregation between sequences and blood viral populations from all time-points were intermingled. Comparison of the average pairwise distance showed the absence of significant viral diversity at the time of primary infection and afterwards during 5 years of full virological control under ART.
CONCLUSION: Despite a slight variation of minority resistance-associated mutation variants, there was no clear evidence of viral evolution during a prolonged period of time in this population of highly controlled adult patients treated at time of PHI.
Errataetall: |
CommentIn: AIDS. 2020 Oct 1;34(12):1855-1856. - PMID 32889855 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
---|---|
Enthalten in: |
AIDS (London, England) - 34(2020), 12 vom: 01. Okt., Seite 1745-1753 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Abdi, Basma [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 18.02.2021 Date Revised 06.05.2021 published: Print CommentIn: AIDS. 2020 Oct 1;34(12):1855-1856. - PMID 32889855 Citation Status MEDLINE |
---|
doi: |
10.1097/QAD.0000000000002629 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM312706235 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM312706235 | ||
003 | DE-627 | ||
005 | 20231225145007.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1097/QAD.0000000000002629 |2 doi | |
028 | 5 | 2 | |a pubmed24n1042.xml |
035 | |a (DE-627)NLM312706235 | ||
035 | |a (NLM)32694418 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Abdi, Basma |e verfasserin |4 aut | |
245 | 1 | 0 | |a No HIV-1 molecular evolution on long-term antiretroviral therapy initiated during primary HIV-1 infection |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 18.02.2021 | ||
500 | |a Date Revised 06.05.2021 | ||
500 | |a published: Print | ||
500 | |a CommentIn: AIDS. 2020 Oct 1;34(12):1855-1856. - PMID 32889855 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a OBJECTIVE: Most studies about HIV-1 molecular evolution have shown the lack of viral evolution on effective antiretroviral therapy (ART), although controversial results have been documented. We therefore aimed to look for evidence of HIV-1 evolution in patients who initiated ART at the time of primary HIV-1 infection (PHI) | ||
520 | |a DESIGN: We included retrospectively 20 patients diagnosed at PHI, treated at the time of acute infection and with subsequent effective long-term suppressive ART (HIV viral load <20 copies/ml during at least 5 years without any blips) | ||
520 | |a METHODS: Longitudinal blood samples were deep sequenced using Illumina Miseq. Drug-resistance-associated mutations were retained at 2% cutoff and interpreted using the latest Agence Nationale de Recherches sur le Sida et les Hépatites Virales resistance algorithm. Viral evolution was established when temporal structure on maximum-likelihood phylogenetic tree and significant change over time of HIV-1 genetic diversity measured as the average pairwise distance was observed | ||
520 | |a RESULTS: Emergences or disappearances of drug-resistance-associated mutations were detected in the blood cells during follow-up despite sustained virological control. In all patients, tree topologies showed an absence of segregation between sequences and blood viral populations from all time-points were intermingled. Comparison of the average pairwise distance showed the absence of significant viral diversity at the time of primary infection and afterwards during 5 years of full virological control under ART | ||
520 | |a CONCLUSION: Despite a slight variation of minority resistance-associated mutation variants, there was no clear evidence of viral evolution during a prolonged period of time in this population of highly controlled adult patients treated at time of PHI | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Anti-HIV Agents |2 NLM | |
700 | 1 | |a Nguyen, Thuy |e verfasserin |4 aut | |
700 | 1 | |a Brouillet, Sophie |e verfasserin |4 aut | |
700 | 1 | |a Desire, Nathalie |e verfasserin |4 aut | |
700 | 1 | |a Sayon, Sophie |e verfasserin |4 aut | |
700 | 1 | |a Wirden, Marc |e verfasserin |4 aut | |
700 | 1 | |a Jary, Aude |e verfasserin |4 aut | |
700 | 1 | |a Achaz, Guillaume |e verfasserin |4 aut | |
700 | 1 | |a Assoumou, Lambert |e verfasserin |4 aut | |
700 | 1 | |a Palich, Romain |e verfasserin |4 aut | |
700 | 1 | |a Simon, Anne |e verfasserin |4 aut | |
700 | 1 | |a Tubiana, Roland |e verfasserin |4 aut | |
700 | 1 | |a Valantin, Marc-Antoine |e verfasserin |4 aut | |
700 | 1 | |a Katlama, Christine |e verfasserin |4 aut | |
700 | 1 | |a Calvez, Vincent |e verfasserin |4 aut | |
700 | 1 | |a Marcelin, Anne-Geneviève |e verfasserin |4 aut | |
700 | 1 | |a Soulie, Cathia |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t AIDS (London, England) |d 1988 |g 34(2020), 12 vom: 01. Okt., Seite 1745-1753 |w (DE-627)NLM012619280 |x 1473-5571 |7 nnns |
773 | 1 | 8 | |g volume:34 |g year:2020 |g number:12 |g day:01 |g month:10 |g pages:1745-1753 |
856 | 4 | 0 | |u http://dx.doi.org/10.1097/QAD.0000000000002629 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 34 |j 2020 |e 12 |b 01 |c 10 |h 1745-1753 |